Pyxis Oncology, Inc. (PYXS) — insider trading
Health Care · NASDAQ
Pyxis Oncology, Inc. (PYXS) has 22 reported SEC Form 4 insider transactions in our data, including 3 open-market purchases and 4 open-market sales among the most recent 22 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D | 10% owner | Open-market purchase (derivative) | 7,172,000 | — | — | Form 4/A |
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D | 10% owner | Open-market purchase (derivative) | 7,546,766 | — | — | Form 4 |
| 2026-10-01 | GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D | 10% owner | Open-market purchase | 5,517,000 | — | — | Form 4 |
| 2026-09-04 | Civik Thomas | Director, Officer (CEO & Chairman of the Board) | Grant / award / vesting (derivative) | 2,503,050 | — | $0 | Form 4 |
| 2026-08-20 | Dupont Jakob | Director | Grant / award / vesting (derivative) | 46,000 | — | $0 | Form 4 |
| 2026-08-12 | Civik Thomas | Director, Officer (Interim CEO) | Grant / award / vesting (derivative) | 250,956 | — | $0 | Form 4 |
| 2026-06-30 | Dupont Jakob | Director | Option exercise / conversion (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-30 | Dupont Jakob | Director | Open-market sale | 35,000 | $3.06 | $107.1K | Form 4 |
| 2026-06-30 | Dupont Jakob | Director | Option exercise / conversion | 35,000 | $1.60 | $56.0K | Form 4 |
| 2026-03-24 | Palani Santhosh | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | HUMPHREY RACHEL | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | Cline Darren S | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | Lewis-Hall Freda C | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | Metzger Michael A | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | FLAVIN JOHN L | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-03-24 | Wadhane Jitendra | Officer (Prin Fin & Acct Officer) | Grant / award / vesting (derivative) | 262,635 | — | $0 | Form 4 |
| 2026-03-24 | Wadhane Jitendra | Officer (Prin Fin & Acct Officer) | Grant / award / vesting | 109,461 | — | $0 | Form 4 |
| 2026-03-24 | Dupont Jakob | Director | Grant / award / vesting (derivative) | 45,867 | — | $0 | Form 4 |
| 2026-02-03 | Civik Thomas | Director, Officer (Interim CEO) | Grant / award / vesting (derivative) | 690,131 | — | $0 | Form 4 |
| 2025-04-21 | HUMPHREY RACHEL | Director | Open-market sale | 13,896 | $1.03 | $14.4K | Form 4 |
| 2025-04-17 | HUMPHREY RACHEL | Director | Open-market sale | 200 | $0.97 | $194 | Form 4 |
| 2025-04-14 | HUMPHREY RACHEL | Director | Open-market sale | 1,400 | $0.9727 | $1.4K | Form 4 |
Ask the chat about PYXS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Pyxis Oncology, Inc. (PYXS).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.